Subtherapeutic Concentrations of Infliximab and Adalimumab Are Associated With Increased Disease Activity in Crohn’s Disease
Therapeutic Advances in Gastroenterology - United Kingdom
doi 10.1177/1756284818759930
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 1, 2018
Authors
Publisher
SAGE Publications